Committee Biographies

DAVID BLUMENTHAL, M.D., M.P.P., is director of the Institute for Health Policy and a physician at the Massachusetts General Hospital/Partners Health Care System in Boston. He is also professor of medicine and professor of health care policy at Harvard Medical School. He is a member of the Institute of Medicine and serves on several journal editorial boards. He is currently executive director for the Commonwealth Fund Task Force on the Future of Academic Health Centers and chairman of the Board of the Massachusetts Peer Review Organization.

R. HENRY BODENBENDER, M.D., is the director of medical services for the Paralyzed Veterans of America. He previously served as acting deputy commander for personnel management at the Naval Medical Command in Washington, D.C., until his retirement from active duty as a captain in the Navy Medical Corps in 1988. He is a board-certified pediatrician. His military awards include the Meritorious Service Medal with Gold Star and the Legion of Merit.

J. LYLE BOOTMAN, Ph.D., is dean and professor of the University of Arizona College of Pharmacy. He is the founding and executive director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research. Dr. Bootman has authored over 200 research articles and monographs and has been an invited speaker at more than 300 professional healthcare meetings and symposia throughout the world. He is a member of the



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 259
DESCRIPTION AND ANALYSIS OF THE VA National Formulary Committee Biographies DAVID BLUMENTHAL, M.D., M.P.P., is director of the Institute for Health Policy and a physician at the Massachusetts General Hospital/Partners Health Care System in Boston. He is also professor of medicine and professor of health care policy at Harvard Medical School. He is a member of the Institute of Medicine and serves on several journal editorial boards. He is currently executive director for the Commonwealth Fund Task Force on the Future of Academic Health Centers and chairman of the Board of the Massachusetts Peer Review Organization. R. HENRY BODENBENDER, M.D., is the director of medical services for the Paralyzed Veterans of America. He previously served as acting deputy commander for personnel management at the Naval Medical Command in Washington, D.C., until his retirement from active duty as a captain in the Navy Medical Corps in 1988. He is a board-certified pediatrician. His military awards include the Meritorious Service Medal with Gold Star and the Legion of Merit. J. LYLE BOOTMAN, Ph.D., is dean and professor of the University of Arizona College of Pharmacy. He is the founding and executive director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research. Dr. Bootman has authored over 200 research articles and monographs and has been an invited speaker at more than 300 professional healthcare meetings and symposia throughout the world. He is a member of the

OCR for page 259
DESCRIPTION AND ANALYSIS OF THE VA National Formulary Institute of Medicine and currently serves as president of the American Pharmaceutical Association. JOHN P. BURKE, M.D., is director of the Department of Clinical Epidemiology, LDS Hospital/Intermountain Health Care and professor of medicine at the University of Utah, where he holds the Ann G. and Jack Mark Presidential Endowed Chair in Medicine. Dr. Burke's primary research interests are in the epidemiology and prevention of adverse clinical outcomes using computer-assisted decision support systems. He is an elected member of the American Epidemiological Society and a Fellow of both the American College of Physicians and the Infectious Diseases Society of America. ELIZABETH DICHTER, M.P.H., is head of strategic marketing at PCS, where she is responsible for creating market opportunities. During her 9 years at PCS, the organization became the leader in managed pharmaceuticals and grew from 15 million to 55 million members. Ms. Dichter spent over 15 years in health policy at both the federal and state levels at the Department of Health and Human Services in Washington, D.C., and in the states of Colorado and Ohio. She has served as advisor to health information and research organizations such as Health Data Institute, Codman Research Group, Knowledge Data Systems, and the Association for Health Services Research. THOMAS R. FULDA, M.A., is program director for Drug Utilization Review at the U.S. Pharmacopoeia, Division of Drug Information Development. He is responsible for the Pharmacopoeia's development of pharmaceutical therapy choice criteria and evidence-based drug-specific criteria for use in prospective DUR, disease management environments. He is also responsible for the development of a disease-specific, annotated, and evaluated bibliography of outcomes and pharmacoeconomic literature. Before joining US Pharmacopoeia, Mr. Fulda was employed by the Health Care Financing Administration, where he received the Department of Health and Human Services Secretary 's Special Achievement Award MARTHA N. HILL, R.N., Ph.D., is a professor and director of the Center for Nursing Research at the Johns Hopkins University School of Nursing. She holds joint appointments in the School of Hygiene and Public Health and the School of Medicine at Johns Hopkins. Dr. Hill was the 1997–1998 president of the American Heart Association; she also serves on numerous review panels, editorial boards, and advisory committees including the Coordinating Committee of the National High Blood Pressure Education Program, the board of directors of the International Society of Hypertension in Blacks, and the American Society of Hypertension.

OCR for page 259
DESCRIPTION AND ANALYSIS OF THE VA National Formulary JOHN D. JONES, J.D., is director of Pharmacy Networks, Public, and Legal Affairs at Prescription Solutions, a pharmacy benefit management company owned by PacifiCare Health Systems. He has been involved in managed care pharmacy practice for 9 years and has been a pharmacist for 24 years. He is also licensed as an attorney in California, where he has applied his legal knowledge in the fields of managed healthcare regulation, pharmacy health insurance, health care contracting and interstate regulatory compliance. Mr. Jones is president for the Academy of Managed Care Pharmacy. He currently sits on the California State Board of Pharmacy. JAMES J. LIPSKY, M.D., is director of clinical pharmacology and professor of medicine and pharmacology at the Mayo Clinic in Rochester, Minnesota. His research involves many aspects of clinical pharmacology, including studies of the mechanism of drug action and toxicity, phamacokinetics, and clinical trials. He serves on the American Board of Clinical Pharmacology and is also a member of the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics. He is a board-certified internist and is a Fellow of the American College of Physicians. He serves on the Minnesota Drug Utilization Review Board and on the Antiviral Drugs Advisory Committee of the Food and Drug Administration ALBERT L. SIU, M.D., is the Clifford L. Spingarn, M.D., Professor of Medicine at the Mount Sinai School of Medicine. He is currently chief of the Division of General Internal Medicine in the Samuel Bronfman Department of Medicine and director of Adult Primary Care (with responsibilities for coordinating the activities of Mount Sinai's Internal Medicine Associates, Coffey Geriatrics Associates, and the Medicine/Pediatrics Associates). He is also a senior associate editor of Health Services Research, a trustee of the Nathan Cummings Foundation, and a member of National Committee for Quality Assurance's Measurement Advisory Panel on geriatrics. FRANK A. SLOAN, Ph.D., has been the J. Alexander McMahon Professor of Health Policy and Management and professor of Economics at Duke University since 1993. He is also director of the Center for Health Policy, Law, and Management at Duke, which was founded in 1998. Previously, he was chair of the Department of Economics at Vanderbilt from 1986 to 1989. His current research interests include alcohol use prevention, long-term care, medical malpractice, and cost-effectiveness analyses of medical technologies. Dr. Sloan also has a long-standing interest in hospitals, health care financing, and health manpower. He is a member of the Institute of Medicine and was recently a member of the Physician Payment Review Commission.

OCR for page 259
DESCRIPTION AND ANALYSIS OF THE VA National Formulary RICHARD A. WANNEMACHER, JR., a combat-disabled Vietnam veteran, is the associate national legislative director of the Disabled American Veterans (DAV). As a member of the DAV’s legislative team, he works to promote rea-sonable and responsible legislation to assist disabled veterans and their families, as well as guarding current veteran’s benefits and services from legislative ero-sion. Mr. Wannemacher earned an associate’s degree in business administration from Erie Community College and a bachelor’s degree in environmental studies from Buffalo State College. He has been with the DAV in various capacities since 1978. OTTO F. WOLKE is currently president and chief executive ofIicer of Schel-len and Partners, USA, Inc., a healthcare consulting company. He was formerly vice president of pharmacy for Penn State Geisinger Health Plan, in Danville, Pennsylvania. In this capacity, he served on the Penn State Geisinger System therapeutics team and provided managed care insights, including on formulary selection, contracting, and utilization management. He currently serves on the Commonwealth of Pennsylvania Medicaid Drug Utilization Review Board, the Technical Advisory Committee for the State of Pennsylvania Pharmaceutical Assistance to the Elderly (PACE) program, and several pharmaceutical company advisory boards. ALLAN ZIMMERMAN is currently senior executive vice president and gen-eral manager of National Prescription Administrators, Inc. (NPA), a privately held, independent pharmacy benefit management company serving over 7 mil-lion members nationally. He directs the marketing, industry relations, profes-sional services, professional relations, vision service, information systems and data administration departments at NPA. He has written numerous articles on managed care pharmacy. He served as president of both the Academy of Man-aged Care Pharmacy and the Foundation for Managed Care Pharmacy.